DNAH7 mutations benefit colorectal cancer patients receiving immune checkpoint inhibitors.

ABSTRACT:

Background

Colorectal cancer (CRC) is a malignant tumor associated with a high mortality rate. While the advent of immune checkpoint inhibitors (ICIs) has been a gamechanger, only a small percentage of CRC patients benefit from ICIs. The pathological mechanism of CRC is not well understood, but somatic mutations, especially missense mutations, are believed to play an important role. This study examined the relationship between ICIs in colorectal cancer and missense mutations in the axonemal dynein heavy chain gene 7 (DNAH7).

Methods

A clinical cohort (n=690) and the CRC data from the publicly available Cancer Genome Atlas (TCGA) were examined. Gene Set Enrichment Analysis, ESTIMATE analysis, and clinical correlation analysis were performed to explore the effects and m

SUBMITTER: Yang W 

PROVIDER: S-EPMC9843387 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature